XPO1 inhibitor selinexor enhances the apoptotic effect of azacitidine in T-cell lymphoma with TET2/RHOA mutations via JAK3/STAT3 axis
Selinexor and azacitidine offer a promising strategy to overcome therapeutic resistance and improve outcomes in TET2/RHOA-mutated PTCL, supporting further clinical evaluation.
Authors
- Y. P. Huang
- Yuran Qiu (ORCID: https://orcid.org/0000-0003-4310-5956)
- Qianqian Zhang (ORCID: https://orcid.org/0000-0002-9564-7346)
- Tingting Xu (ORCID: https://orcid.org/0000-0002-9704-7125)
- Ming-Ci Cai
- Li Wang
- Wei-Li Zhao
- Shu Cheng
- Peng-Peng Xu
Institutions
- Shanghai Jiao Tong University (CN)
- Ruijin Hospital (CN)
- Institut Français de la Vigne et du Vin (FR)
- Shanghai Institute of Hematology (CN)
Publication Details
- Journal
- Cell Communication and Signaling
- Published
- 2025-12-23
- DOI
- https://doi.org/10.1186/s12964-025-02507-2
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Shanghai Hospital Development Center